Kenvue Inc. (NYSE:KVUE) Receives Consensus Rating of “Hold” from Brokerages

Kenvue Inc. (NYSE:KVUE) has been given an average recommendation of “Hold” by the sixteen brokerages that are covering the firm, Marketbeat reports. Thirteen analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $19.3333.

A number of equities analysts recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a research note on Wednesday, April 8th. Argus raised shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. UBS Group dropped their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Finally, Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $23.00 to $18.00 in a research note on Friday, January 30th.

Kenvue Trading Down 0.1%

Shares of NYSE KVUE opened at $17.58 on Tuesday. The business’s 50 day moving average is $17.91 and its two-hundred day moving average is $17.12. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue has a 1-year low of $14.02 and a 1-year high of $25.17. The stock has a market capitalization of $33.76 billion, a P/E ratio of 22.84, a PEG ratio of 4.00 and a beta of 0.61.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The company had revenue of $3.78 billion for the quarter, compared to analysts’ expectations of $3.68 billion. During the same period in the previous year, the firm posted $0.26 earnings per share. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. As a group, research analysts expect that Kenvue will post 1.1 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. Kenvue’s payout ratio is currently 107.79%.

Institutional Investors Weigh In On Kenvue

Several large investors have recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System bought a new stake in shares of Kenvue in the 1st quarter valued at about $1,683,000. Kestra Private Wealth Services LLC raised its stake in Kenvue by 46.7% in the first quarter. Kestra Private Wealth Services LLC now owns 77,058 shares of the company’s stock worth $1,328,000 after buying an additional 24,541 shares in the last quarter. Oak Family Advisors LLC raised its stake in Kenvue by 35.4% in the first quarter. Oak Family Advisors LLC now owns 471,239 shares of the company’s stock worth $8,124,000 after buying an additional 123,214 shares in the last quarter. OP Asset Management Ltd bought a new position in Kenvue in the first quarter worth approximately $3,438,000. Finally, Banque Cantonale Vaudoise raised its stake in Kenvue by 4.0% in the first quarter. Banque Cantonale Vaudoise now owns 61,706 shares of the company’s stock worth $1,063,000 after buying an additional 2,370 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.